Shares of Novo Nordisk (NYSE: NVO) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P 500 lost 2.4%, and the Nasdaq-100 lost 2.2%. The Danish pharmaceutical giant's stock was hit after it released disappointing earnings showing that sales of its blockbuster GLP-1 drugs remain weaker than hoped.

Novo Nordisk is a healthcare stock that is down 50% in 2025. Is NVO stock undervalued at current levels or can it move lower over the next 12 months?

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.